AIF1 and migraine disorder: The glycolysis inhibitor 2-DG significantly inhibited the symptoms of migraine, and the underlying mechanisms included inhibition of microglia activation, inhibition of Iba-1/proBDNF/BDNF pathway, and the release of inflammatory and neurogenic inflammatory factors.